A5036484442- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Extracellular vesicles in disease
- RNA Interference and Gene Delivery
- Immunotherapy and Immune Responses
- Liver Disease Diagnosis and Treatment
- Cancer Research and Treatments
- Glycosylation and Glycoproteins Research
- Phagocytosis and Immune Regulation
- CAR-T cell therapy research
- SARS-CoV-2 and COVID-19 Research
The University of Texas MD Anderson Cancer Center
2023-2025
Mutations in KRAS are a dominant driver of pancreatic ductal adenocarcinoma (PDAC), with over 40% PDAC patients presenting G12D mutations. The recent development small molecule inhibitors targeting has enabled mutant signaling and suppression PDAC; however, the contribution tumor microenvironment (TME) to sustained therapeutic efficacy inhibition mechanism/s resistance remain be elucidated. Here, we employed spatial transcriptomics, single cell RNA sequencing, CODEX-based proteomics evaluate...
Abstract Lack of sustained response to oncogenic Kras (Kras*) inhibition in preclinical models and patients with pancreatic ductal adenocarcinoma (PDAC) emphasizes the need identify impactful synergistic combination therapies achieve robust clinical benefit. Kras* targeting results an influx global T cell infiltrates including Tregs, effector CD8 + cells exhausted expressing several immune checkpoint molecules PDAC. Here, we probe whether induced by diverse inhibitors open a therapeutic...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is associated with mutations in Kras, a known oncogenic driver of PDAC; and the KRAS G12D mutation present nearly half PDAC patients. Recently, non-covalent small molecule inhibitor (MRTX1133) was identified specificity to Kras mutant protein. Here we explore impact inhibition by MRTX1133 on advanced its influence tumor microenvironment. Employing different orthotopic xenograft syngeneic models, eight PDXs, two autochthonous genetic...
Abstract Mutations in KRAS are a dominant driver of pancreatic ductal adenocarcinoma (PDAC), with over 50% PDAC patients presenting KRASG12D mutations. The recent development small molecule inhibitors targeting has enabled effective mutant signaling and suppression tumor growth; however, the contribution microenvironment to therapeutic efficacy inhibition mechanisms resistance remain be fully elucidated. Here, we employed spatial transcriptomics proteomics evaluate cancer cell intrinsic...
Abstract mRNA incorporated in lipid nanoparticles (LNPs) became a new class of vaccine modality for induction immunity against COVID-19 and ushered era development. Here, we report novel, easy-to-execute, cost effective engineered extracellular vesicles (EVs)-based combined protein platform (EV X-M+P vaccine) explore its utility proof-of-concept studies the settings cancer infectious disease. As first example, EVs to contain ovalbumin OvaM+P ) serve as ovalbumin-expressing melanoma tumors....